Using exosomes to deliver RNA therapies for aggressive breast cancer treatment
TNBC Ligand-displaying Exosomes Using RNA Nanotechnology for Targeted Cytosol Delivery of RNAi without Endosome Entrapment
This study is exploring a new way to deliver RNA treatments directly to triple negative breast cancer cells using tiny carriers called exosomes, which could help make these therapies work better for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11086639 on NIH RePORTER |
What this research studies
This research focuses on developing a novel method to deliver RNA-based therapies specifically to triple negative breast cancer (TNBC) cells using exosomes, which are tiny vesicles that can carry therapeutic molecules. The approach aims to avoid the common issue of endosomal entrapment, which often limits the effectiveness of RNA therapies. By decorating the surfaces of exosomes with specific targeting ligands, the researchers hope to enhance the delivery of RNA interference (RNAi) therapeutics directly into the cytosol of cancer cells, potentially improving treatment outcomes for patients with TNBC. The study builds on previous findings that demonstrated the effectiveness of this delivery method in inhibiting cancer cell growth in laboratory models.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have limited treatment options.
Not a fit: Patients with other subtypes of breast cancer or those who are not eligible for RNAi therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple negative breast cancer, improving survival rates and quality of life.
How similar studies have performed: Previous studies have shown promising results using similar RNA delivery methods, indicating potential for success in this novel approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Shu, Dan — Ohio State University
- Study coordinator: Shu, Dan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.